{"id":1248,"date":"2018-10-15T09:04:14","date_gmt":"2018-10-15T09:04:14","guid":{"rendered":"https:\/\/igemtherapeutics.com\/?p=1248"},"modified":"2018-10-15T09:04:14","modified_gmt":"2018-10-15T09:04:14","slug":"igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards","status":"publish","type":"post","link":"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/","title":{"rendered":"IGEM Therapeutics awarded \u201cBest Start-up Biotech Company\u201d at the 2018 OBN Awards"},"content":{"rendered":"<p><img decoding=\"async\" class=\"alignnone wp-image-1273\" src=\"https:\/\/igemtherapeutics.com\/wp-content\/uploads\/2018\/10\/Best-Start-up-Biotech-Company-IGEM-Therapeutics.jpg\" alt=\"\" width=\"100%\" \/><\/p>\n<p><strong>London, 12 October 2018<\/strong> \u2013 IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced that it has won the \u201cBest Start-up Biotech Company\u201d award at the OBN Awards 2018.<\/p>\n<p>The award recognises IGEM Therapeutics as a UK registered start-up biotech company making a significant impact in the sector through news flow, successful fundraising and execution of a robust business plan. The ceremony on Thursday 11 October marked the 10<sup>th<\/sup> anniversary of the OBN Awards, which celebrate success stories from the UK life sciences industry over the past year.<\/p>\n<p><strong>Dr Tim Wilson, Chief Executive Officer of IGEM Therapeutics, commented<\/strong>: \u201cWe are thrilled that IGEM Therapeutics Therapeutics has been awarded \u201cBest Start-up Biotech Company\u201d at this year\u2019s prestigious OBN Awards. The award recognises our efforts to treat cancer by developing novel immunoglobin E antibodies and our significant progress as a company over the last year.\u201d<\/p>\n<p>&nbsp;<\/p>\n<p><strong>About IGEM Therapeutics<\/strong><\/p>\n<p>IGEM Therapeutics is a UK immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer. Unlike immunoglobulin G (IgG), IgE has evolved to kill tissue-dwelling multicellular parasites endowing it with several key features that make it ideal for the treatment of solid tumours.<\/p>\n<p>Pre-clinical proof of concept has been obtained with two different IgE antibodies both showing significantly greater efficacy versus IgG comparators. IGEM Therapeutics is a spin out of King\u2019s College London with financing from Epidarex Capital and has an ongoing collaboration with Dr. Sophia Karagiannis, a global leader in the understanding of IgE antibodies.<\/p>\n<p>For further information visit <a href=\"https:\/\/epsilogen.com\/\">www.epsilogen.com<\/a><\/p>\n<p><strong>For more information please contact:<\/strong><\/p>\n<p>Tim Wilson<\/p>\n<p>Chief Executive Officer<\/p>\n<p>IGEM Therapeutics<\/p>\n<p><a href=\"mailto:tim@epsilgen.com\">tim@epsilogen.com<\/a><\/p>\n<p>+44 (0)20 3078 9675<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Communications advisor to IGEM Therapeutics:<\/strong><\/p>\n<p>Simon Conway<\/p>\n<p>Senior Managing Director<\/p>\n<p>FTI Consulting<\/p>\n<p><a href=\"mailto:simon.conway@fticonsulting.com\">simon.conway@fticonsulting.com<\/a><\/p>\n<p>+44 (0)20 3727 1000<\/p>\n","protected":false},"excerpt":{"rendered":"<p>London, 12 October 2018 \u2013 IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced that it has won the \u201cBest Start-up Biotech Company\u201d award at the OBN Awards 2018. The award recognises IGEM Therapeutics as a UK registered start-up biotech company making a significant impact in the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[9],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>IGEM Therapeutics awarded \u201cBest Start-up Biotech Company\u201d at the 2018 OBN Awards - Epsilogen<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IGEM Therapeutics awarded \u201cBest Start-up Biotech Company\u201d at the 2018 OBN Awards - Epsilogen\" \/>\n<meta property=\"og:description\" content=\"London, 12 October 2018 \u2013 IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced that it has won the \u201cBest Start-up Biotech Company\u201d award at the OBN Awards 2018. The award recognises IGEM Therapeutics as a UK registered start-up biotech company making a significant impact in the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/\" \/>\n<meta property=\"og:site_name\" content=\"Epsilogen\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-15T09:04:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/igemtherapeutics.com\/wp-content\/uploads\/2018\/10\/Best-Start-up-Biotech-Company-IGEM-Therapeutics.jpg\" \/>\n<meta name=\"author\" content=\"Daniel\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Daniel\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/\"},\"author\":{\"name\":\"Daniel\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/person\/25beed45dd34b674c4e479b4132fa3a0\"},\"headline\":\"IGEM Therapeutics awarded \u201cBest Start-up Biotech Company\u201d at the 2018 OBN Awards\",\"datePublished\":\"2018-10-15T09:04:14+00:00\",\"dateModified\":\"2018-10-15T09:04:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/\"},\"wordCount\":299,\"publisher\":{\"@id\":\"https:\/\/epsilogen.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/igemtherapeutics.com\/wp-content\/uploads\/2018\/10\/Best-Start-up-Biotech-Company-IGEM-Therapeutics.jpg\",\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/\",\"url\":\"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/\",\"name\":\"IGEM Therapeutics awarded \u201cBest Start-up Biotech Company\u201d at the 2018 OBN Awards - Epsilogen\",\"isPartOf\":{\"@id\":\"https:\/\/epsilogen.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/igemtherapeutics.com\/wp-content\/uploads\/2018\/10\/Best-Start-up-Biotech-Company-IGEM-Therapeutics.jpg\",\"datePublished\":\"2018-10-15T09:04:14+00:00\",\"dateModified\":\"2018-10-15T09:04:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/#primaryimage\",\"url\":\"https:\/\/igemtherapeutics.com\/wp-content\/uploads\/2018\/10\/Best-Start-up-Biotech-Company-IGEM-Therapeutics.jpg\",\"contentUrl\":\"https:\/\/igemtherapeutics.com\/wp-content\/uploads\/2018\/10\/Best-Start-up-Biotech-Company-IGEM-Therapeutics.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/epsilogen.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IGEM Therapeutics awarded \u201cBest Start-up Biotech Company\u201d at the 2018 OBN Awards\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/epsilogen.com\/#website\",\"url\":\"https:\/\/epsilogen.com\/\",\"name\":\"Epsilogen\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/epsilogen.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/epsilogen.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/epsilogen.com\/#organization\",\"name\":\"Epsilogen\",\"url\":\"https:\/\/epsilogen.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg\",\"contentUrl\":\"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg\",\"width\":267,\"height\":64,\"caption\":\"Epsilogen\"},\"image\":{\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/person\/25beed45dd34b674c4e479b4132fa3a0\",\"name\":\"Daniel\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/338bc7609426d1862789601c4efdafb0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/338bc7609426d1862789601c4efdafb0?s=96&d=mm&r=g\",\"caption\":\"Daniel\"},\"sameAs\":[\"https:\/\/epsilogen.com\"],\"url\":\"https:\/\/epsilogen.com\/author\/daniel\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IGEM Therapeutics awarded \u201cBest Start-up Biotech Company\u201d at the 2018 OBN Awards - Epsilogen","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/","og_locale":"en_US","og_type":"article","og_title":"IGEM Therapeutics awarded \u201cBest Start-up Biotech Company\u201d at the 2018 OBN Awards - Epsilogen","og_description":"London, 12 October 2018 \u2013 IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced that it has won the \u201cBest Start-up Biotech Company\u201d award at the OBN Awards 2018. The award recognises IGEM Therapeutics as a UK registered start-up biotech company making a significant impact in the [&hellip;]","og_url":"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/","og_site_name":"Epsilogen","article_published_time":"2018-10-15T09:04:14+00:00","og_image":[{"url":"https:\/\/igemtherapeutics.com\/wp-content\/uploads\/2018\/10\/Best-Start-up-Biotech-Company-IGEM-Therapeutics.jpg"}],"author":"Daniel","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Daniel","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/#article","isPartOf":{"@id":"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/"},"author":{"name":"Daniel","@id":"https:\/\/epsilogen.com\/#\/schema\/person\/25beed45dd34b674c4e479b4132fa3a0"},"headline":"IGEM Therapeutics awarded \u201cBest Start-up Biotech Company\u201d at the 2018 OBN Awards","datePublished":"2018-10-15T09:04:14+00:00","dateModified":"2018-10-15T09:04:14+00:00","mainEntityOfPage":{"@id":"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/"},"wordCount":299,"publisher":{"@id":"https:\/\/epsilogen.com\/#organization"},"image":{"@id":"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/#primaryimage"},"thumbnailUrl":"https:\/\/igemtherapeutics.com\/wp-content\/uploads\/2018\/10\/Best-Start-up-Biotech-Company-IGEM-Therapeutics.jpg","articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/","url":"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/","name":"IGEM Therapeutics awarded \u201cBest Start-up Biotech Company\u201d at the 2018 OBN Awards - Epsilogen","isPartOf":{"@id":"https:\/\/epsilogen.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/#primaryimage"},"image":{"@id":"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/#primaryimage"},"thumbnailUrl":"https:\/\/igemtherapeutics.com\/wp-content\/uploads\/2018\/10\/Best-Start-up-Biotech-Company-IGEM-Therapeutics.jpg","datePublished":"2018-10-15T09:04:14+00:00","dateModified":"2018-10-15T09:04:14+00:00","breadcrumb":{"@id":"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/#primaryimage","url":"https:\/\/igemtherapeutics.com\/wp-content\/uploads\/2018\/10\/Best-Start-up-Biotech-Company-IGEM-Therapeutics.jpg","contentUrl":"https:\/\/igemtherapeutics.com\/wp-content\/uploads\/2018\/10\/Best-Start-up-Biotech-Company-IGEM-Therapeutics.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/epsilogen.com\/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/epsilogen.com\/"},{"@type":"ListItem","position":2,"name":"IGEM Therapeutics awarded \u201cBest Start-up Biotech Company\u201d at the 2018 OBN Awards"}]},{"@type":"WebSite","@id":"https:\/\/epsilogen.com\/#website","url":"https:\/\/epsilogen.com\/","name":"Epsilogen","description":"","publisher":{"@id":"https:\/\/epsilogen.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/epsilogen.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/epsilogen.com\/#organization","name":"Epsilogen","url":"https:\/\/epsilogen.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/","url":"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg","contentUrl":"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg","width":267,"height":64,"caption":"Epsilogen"},"image":{"@id":"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/epsilogen.com\/#\/schema\/person\/25beed45dd34b674c4e479b4132fa3a0","name":"Daniel","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/epsilogen.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/338bc7609426d1862789601c4efdafb0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/338bc7609426d1862789601c4efdafb0?s=96&d=mm&r=g","caption":"Daniel"},"sameAs":["https:\/\/epsilogen.com"],"url":"https:\/\/epsilogen.com\/author\/daniel\/"}]}},"_links":{"self":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/posts\/1248"}],"collection":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/comments?post=1248"}],"version-history":[{"count":0,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/posts\/1248\/revisions"}],"wp:attachment":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/media?parent=1248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/categories?post=1248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/tags?post=1248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}